Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

VIP vs Oxytocin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Oxytocin has stronger documented evidence (FDA-Approved) than VIP (Phase 3 (Aviptadil) / Off-Label) while both occupy the neuropeptide class. When clinical-evidence tier is the deciding factor, Oxytocin is the safer pick. VIP may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

VIP

Phase 3 (Aviptadil) / Off-Label

Oxytocin

FDA-Approved

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: hypotension. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

VIP Oxytocin
Class Neuropeptide hormone; multi-organ regulator Posterior pituitary hormone
Drug class Other & Emerging Sexual-Health
Mechanism VPAC1/VPAC2 receptor agonist; vasodilation; anti-inflammatory; surfactant production OXT receptor agonist; uterine contraction; social bonding and stress regulation pathways
Route Intranasal / IV / SC IV / IM / Intranasal / SC
Half-life ~1-2 min (IV) ~3-5 min (IV)
Dosage (research) Intranasal 50-100 mcg 4x daily (off-label); IV in COVID trials 10 IU intranasal daily for bonding off-label (Heinrichs et al. paradigm starting dose, max 40 IU/day in research trials); 10 IU IM post-partum (FDA Pitocin label dose for uterine atony)
Evidence tier Phase 3 (Aviptadil) / Off-Label FDA-Approved
Research depth 161 indexed (PubMed 142 · CT 4 · EPMC 15) 332 indexed (PubMed 205 · CT 70 · EPMC 57)
Availability Investigational / Compounded Prescription
Reported risks Hypotension; flushing; diarrhea Hyponatremia with high doses; hypotension; allergic reactions

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick VIP or Oxytocin?

Oxytocin has stronger documented evidence (FDA-Approved) than VIP (Phase 3 (Aviptadil) / Off-Label) while both occupy the neuropeptide class. When clinical-evidence tier is the deciding factor, Oxytocin is the safer pick. VIP may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between VIP and Oxytocin?

VIP is classed as Neuropeptide hormone; multi-organ regulator; Oxytocin is classed as Posterior pituitary hormone. Reported mechanism: VIP, VPAC1/VPAC2 receptor agonist; vasodilation; anti-inflammatory; surfactant production; Oxytocin, OXT receptor agonist; uterine contraction; social bonding and stress regulation pathways. Reported half-life: VIP, ~1-2 min (IV); Oxytocin, ~3-5 min (IV). Routes in published studies: VIP, Intranasal / IV / SC; Oxytocin, IV / IM / Intranasal / SC.

Which has stronger evidence, VIP or Oxytocin?

Oxytocin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. VIP is graded Phase 3 (Aviptadil) / Off-Label, with 19 cited sources on its reference page and 161 indexed studies. Oxytocin is graded FDA-Approved, with 73 cited sources on its reference page and 332 indexed studies.

Which is more accessible, VIP or Oxytocin?

Oxytocin is FDA-approved and VIP is not. Catalog status: VIP, Investigational / Compounded; Oxytocin, Prescription.

Are VIP and Oxytocin ever combined?

VIP and Oxytocin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…